Doktornolittle,
DCVax-Lung may be the trade off name for improved L created during manufacturing upgrades for commercialization and or safety concerns. Remember, NIH has a patented process improvement linked to this trial. There may very well be other improvements from Fraunhofer or Cognate combined with knowledge gained from Direct Phase 1 from NWBO. I would expect tangential flow filtration and microchip cell selectivity as well as improved recipe to be involved in this trial. How else do you put DCVax-Lung Up as a control unless it is suspected to be as good or better than any other existing treatment. I think we may have some big bets going on in this trial. In the past, DC treatment may have been as good as a placebo in recurrent GBM patients. Maybe that is why BMY agreed to cosponsor this trial. On the other hand, with the improved dosing regimen and now 6 minimum treatments perhaps NWBO is ready to come out swinging with an improved version of L. What a surprise if monotherapy performs as well as the combo and complete responses occur.
Think about what might have happened in the Spring of 2015. Did data refresh show early results from a German claim to improving L during the Phase 3? After her long battle Kat's Cure comes in all of the sudden. Something to consider is how her treatment might have been made. Best wishes.
News 
Market Data 
Discover 
AI
